---
schema_version: "secwatch.filing_event.v1"
accession: "0001178670-25-000020"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:06:12.353851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q4 product rev $451M (+30%); FY rev $1.65B (+33%); vutrisiran sNDA PDUFA Mar 23

## Summary
- Q4 2024 global net product revenues $451M (+30% vs Q4 2023); full year $1,646M (+33%).
- Q4 total revenues $593.2M; net loss $83.8M improved from $137.9M loss in Q4 2023.
- FDA accepted sNDA for vutrisiran in ATTR cardiomyopathy; PDUFA target date March 23, 2025.
- Non-GAAP net income of $8.0M in Q4 vs loss of $96.6M in prior year.
- Company reiterates 2025 product sales and profitability guidance; R&D Day Feb 25, 2025.

## SEC filing metadata
- accession: 0001178670-25-000020
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000020/0001178670-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000117867025000020/alny-20250213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178670-25-000020
- JSON: https://secwatch.observer/filing/0001178670-25-000020.json
- Plain text: https://secwatch.observer/filing/0001178670-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.